Dr. Vimal Kumar Derebail, MD

Dr. Derebail practices at UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System.

Dr. Derebail's NPI, 1639381999, was assigned on May 7, 2007. Dr. Derebail graduated from Medical College of Georgia School of Medicine in 2002. Dr. Derebail holds North Carolina license 2005-00740.

Dr. Derebail's primary practice is UNC Hospitals, at 101 Manning Drive, Chapel Hill, NC 27514 in Orange County. The practice phone is (919) 966-4141.

Dr. Derebail's primary practice is UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System. Dr. Derebail is also affiliated with UNC Health Rex. The medical group on file is UNC Faculty Physicians. Dmand AI also links Dr. Derebail to 2 more group practices and clinics, 1 therapy and rehab clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Derebail practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Derebail's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Derebail is licensed in North Carolina.

CMS data shows 528 Medicare services from Dr. Derebail across 9 procedure codes in 2024, for 178 Medicare patients. Medicare paid $36,084 for them.

CMS counts 178 Medicare patients who saw Dr. Derebail in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 26% are also on Medicaid. Their average risk score is 4.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Derebail's median patient age at 68, with 60% women.

In 2024, Dr. Derebail wrote 652 Medicare Part D claims for 78 patients. 89% of them were for generic drugs. CMS names the drug for 411 of them, across 19 drugs with 11 or more claims each, at $18,282 in total drug cost. In 2023, CMS named 483 claims across 21 drugs.

Dr. Derebail accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Derebail as offering telehealth.

Dmand AI links 54 papers to Dr. Derebail, published from 2020 to 2025. 2024 was the busiest year, with 12. The most frequent topics are Anemia, Sickle Cell, Renal Insufficiency, Chronic and Antibodies, Antineutrophil Cytoplasmic. Dr. Derebail has published most often in Kidney Int Rep. Dr. Derebail's most frequent co-authors are Nigel S. Key, MD, Santosh Lumdas Saraf, MD and Kenneth I. Ataga, MD.

CMS Open Payments shows 55 general payments to Dr. Derebail from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Novartis Pharmaceuticals Corporation paid the most, $16,892. It also lists 5 research payments totaling $2,013 from 2018 to 2019.

Dr. Derebail graduated from Medical College of Georgia School of Medicine in 2002.